191 related articles for article (PubMed ID: 37251557)
1. Efficacy and Safety of TACE Combined with Regorafenib versus TACE in the Third-Line Treatment of Colorectal Liver Metastases.
Lu H; Zheng C; Fan L; Xiong B
J Oncol; 2022; 2022():5366011. PubMed ID: 37251557
[TBL] [Abstract][Full Text] [Related]
2. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.
Cao F; Zheng J; Luo J; Zhang Z; Shao G
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2993-3002. PubMed ID: 34302208
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
Yu W; Tao Q; Zhang Y; Yi F; Feng L
J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
[TBL] [Abstract][Full Text] [Related]
5. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases.
Zhao G; Liu S; Zhang Y; Zhao T; Wang R; Bian J; Wu J; Zhou J
Ir J Med Sci; 2022 Jun; 191(3):1139-1145. PubMed ID: 34264426
[TBL] [Abstract][Full Text] [Related]
8. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
Front Oncol; 2022; 12():917353. PubMed ID: 36226061
[TBL] [Abstract][Full Text] [Related]
10. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
11. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance.
Zou X; Xu Q; You R; Yin G
J Hepatocell Carcinoma; 2023; 10():267-279. PubMed ID: 36815093
[TBL] [Abstract][Full Text] [Related]
14. Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study.
Su M; Chen S; Li S; Xu F; Zhao G; Qu J; Zhou J
J Gastrointest Oncol; 2022 Dec; 13(6):3183-3192. PubMed ID: 36636092
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.
Xu D; Liu Y; Tang W; Xu L; Liu T; Jiang Y; Zhou S; Qin X; Li J; Zhao J; Ye L; Chang W; Xu J
Front Oncol; 2022; 12():838870. PubMed ID: 35433423
[TBL] [Abstract][Full Text] [Related]
16. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of raltitrexed plus S-1
Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
[TBL] [Abstract][Full Text] [Related]
19. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
